$ACOG gets positive preclinical results for ALPHA-0602 drug For those interested in the biopharma space, Alpha Cognition Inc. ($ACOG.v $ACOGF) is a company working on creating medication to help those with neurodegenerative disorders.
It recently announced that it received positive preclinical data from its ALPHA-0602 gene therapy program.
$ACOG's ALPHA-0602 is designed to increase brain progranulin levels and reduce the effects of oxidative stress which is associated with ALS.
Pre-clinical results demonstrated that ALPHA-0602 further increased progranulin levels and decreased motor neuron cell death in in vitro models along with other positive results.
Full results here: https://finance.yahoo.com/news/alpha-cognition-announces-positive-data-130000103.html
IMO these results are a big step forward for $ACOG and its ALPHA-0602 drug. Considering the lack of available medicines for ALS $ACOG could really blow up as it moves its drugs towards approval phases.
$ACOG @ $1.03
MC $63.341M